Home LiteratureArticle Details
PMID: 21958944 Published · ppublish English Journal Article Review

Genetically engineered murine models--contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma.

Seminars in cancer biology ·Vol. 21 ·No. 4 ·2011-10-00 ·Pages 245-55

Chesler L, Weiss WA

Abstract

Genetically engineered mouse models (GEMM) have made major contributions to a molecular understanding of several adult cancers and these results are increasingly being translated into the pre-clinical setting where GEMM will very likely make a major impact on the development of targeted therapeutics in the near future. The relationship of pediatric cancers to altered developmental programs, and their genetic simplicity relative to adult cancers provides unique opportunities for the application of new advances in GEMM technology. In neuroblastoma the well-characterized TH-MYCN GEMM is increasingly used for a variety of molecular-genetic, developmental and pre-clinical therapeutics applications. We discuss: the present and historical application of GEMM to neuroblastoma research, future opportunities, and relevant targets suitable for new GEMM strategies in neuroblastoma. We review the potential of these models to contribute both to an understanding of the developmental nature of neuroblastoma and to improved therapy for this disease.

MeSH Terms
Animals Child Disease Models, Animal Genetic Engineering/methods,trends Humans Mice Neuroblastoma/genetics,pathology,therapy Pathology, Molecular/methods,trends
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Chesler Louis
Division of Clinical Studies and Cancer Therapeutics, The Institute of Cancer Research & The Royal Marsden NHS Trust, Sutton, Surrey SM2 5NG, United Kingdom. Louis.Chesler@icr.ac.uk
Weiss William A
References (155)
155 references, click to expand
  1. MYCN regulates oncogenic MicroRNAs in neuroblastoma.
    Int J Cancer. 2008 Feb 1;122(3):699-704 PMID: 17943719
  2. Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis.
    Cancer Res. 2007 Feb 1;67(3):976-83 PMID: 17283129
  3. CHD5, a new member of the chromodomain gene family, is preferentially expressed in the nervous system.
    Oncogene. 2003 Feb 20;22(7):1002-11 PMID: 12592387
  4. The Myc/Max/Mad network and the transcriptional control of cell behavior.
    Annu Rev Cell Dev Biol. 2000;16:653-99 PMID: 11031250
  5. Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction.
    Neoplasia. 2008 Nov;10(11):1268-74 PMID: 18953436
  6. Multiple arrangements of viral DNA and an activated host oncogene in bursal lymphomas.
    Nature. 1982 Jan 21;295(5846):209-14 PMID: 6276760
  7. Myc-regulated microRNAs attenuate embryonic stem cell differentiation.
    EMBO J. 2009 Oct 21;28(20):3157-70 PMID: 19745813
  8. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN.
    Nat Med. 2000 May;6(5):529-35 PMID: 10802708
  9. CXCR5 may be involved in the attraction of human metastatic neuroblastoma cells to the bone marrow.
    Cancer Immunol Immunother. 2008 Apr;57(4):541-8 PMID: 17786442
  10. Identification of ALK as a major familial neuroblastoma predisposition gene.
    Nature. 2008 Oct 16;455(7215):930-5 PMID: 18724359
  11. Credentialing a preclinical mouse model of alveolar rhabdomyosarcoma.
    Cancer Res. 2009 Apr 1;69(7):2902-11 PMID: 19339268
  12. Tet repressor-based system for regulated gene expression in eukaryotic cells: principles and advances.
    Methods Enzymol. 2000;327:401-21 PMID: 11044999
  13. The connections between neural crest development and neuroblastoma.
    Curr Top Dev Biol. 2011;94:77-127 PMID: 21295685
  14. Mouse models for the study of telomerase.
    Ciba Found Symp. 1997;211:160-70; discussion 170-6 PMID: 9524757
  15. Accumulation of segmental alterations determines progression in neuroblastoma.
    J Clin Oncol. 2010 Jul 1;28(19):3122-30 PMID: 20516441
  16. Proto-oncogene c-myc is expressed in cerebellar neurons at different developmental stages.
    EMBO J. 1986 Aug;5(8):1897-901 PMID: 2428614
  17. Modeling human lung cancer in mice: similarities and shortcomings.
    Oncogene. 1999 Sep 20;18(38):5318-24 PMID: 10498884
  18. Tissue microenvironment modulates CXCR4 expression and tumor metastasis in neuroblastoma.
    Neoplasia. 2007 Jan;9(1):36-46 PMID: 17325742
  19. Neuroblastoma epigenetics: from candidate gene approaches to genome-wide screenings.
    Epigenetics. 2011 Aug;6(8):962-70 PMID: 21725203
  20. Regions syntenic to human 17q are gained in mouse and rat neuroblastoma.
    Genes Chromosomes Cancer. 2004 Jun;40(2):158-63 PMID: 15101050
  21. Resistance to TRAIL-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression.
    Med Pediatr Oncol. 2000 Dec;35(6):603-7 PMID: 11107127
  22. PHOX2A and PHOX2B genes are highly co-expressed in human neuroblastoma.
    Int J Oncol. 2008 Nov;33(5):985-91 PMID: 18949361
  23. Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastoma.
    J Natl Cancer Inst. 2003 Sep 17;95(18):1394-403 PMID: 13130115
  24. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer.
    Science. 2009 Jun 12;324(5933):1457-61 PMID: 19460966
  25. Linking functional decline of telomeres, mitochondria and stem cells during ageing.
    Nature. 2010 Mar 25;464(7288):520-8 PMID: 20336134
  26. The Myc oncoprotein as a therapeutic target for human cancer.
    Semin Cancer Biol. 2006 Aug;16(4):318-30 PMID: 16934487
  27. Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.
    Cancer Res. 2000 Aug 15;60(16):4315-9 PMID: 10969767
  28. Myc overexpression enhances apoptosis induced by small molecules.
    Cell Cycle. 2006 Oct;5(19):2191-4 PMID: 17012843
  29. Methionine aminopeptidase 2 inhibition is an effective treatment strategy for neuroblastoma in preclinical models.
    Clin Cancer Res. 2005 Apr 1;11(7):2680-5 PMID: 15814649
  30. Activating mutations in ALK provide a therapeutic target in neuroblastoma.
    Nature. 2008 Oct 16;455(7215):975-8 PMID: 18923525
  31. Molecular pathogenesis of peripheral neuroblastic tumors.
    Oncogene. 2010 Mar 18;29(11):1566-79 PMID: 20101209
  32. Cell lines from MYCN transgenic murine tumours reflect the molecular and biological characteristics of human neuroblastoma.
    Eur J Cancer. 2007 Jun;43(9):1467-75 PMID: 17449239
  33. Pinhole imaging of 131I-metaiodobenzylguanidine (131I-MIBG) in an animal model of neuroblastoma.
    Pediatr Radiol. 2003 Oct;33(10):688-92 PMID: 12908090
  34. Oncogenic mutations of ALK kinase in neuroblastoma.
    Nature. 2008 Oct 16;455(7215):971-4 PMID: 18923524
  35. Mouse models of childhood cancer of the nervous system.
    J Clin Pathol. 2004 Jun;57(6):561-76 PMID: 15166259
  36. Derivation of neural crest cells from human pluripotent stem cells.
    Nat Protoc. 2010 Apr;5(4):688-701 PMID: 20360764
  37. PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma.
    J Clin Oncol. 2008 Nov 20;26(33):5443-9 PMID: 18838715
  38. Chromosome 6p22 locus associated with clinically aggressive neuroblastoma.
    N Engl J Med. 2008 Jun 12;358(24):2585-93 PMID: 18463370
  39. Modeling cancer in the mouse.
    Harvey Lect. 2005-2006;101:1-19 PMID: 18030972
  40. Detecting minimal residual disease in neuroblastoma patients-the present state of the art.
    Cancer Lett. 2005 Oct 18;228(1-2):229-40 PMID: 15951104
  41. MYCN downregulates integrin alpha1 to promote invasion of human neuroblastoma cells.
    Int J Oncol. 2008 Oct;33(4):815-21 PMID: 18813796
  42. Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification.
    Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12664-9 PMID: 15314226
  43. DRR1 is expressed in the developing nervous system and downregulated during neuroblastoma carcinogenesis.
    Biochem Biophys Res Commun. 2010 Apr 9;394(3):829-35 PMID: 20298674
  44. Mutations in PIK3CA are infrequent in neuroblastoma.
    BMC Cancer. 2006 Jul 05;6:177 PMID: 16822308
  45. Exploring the genomes of cancer cells: progress and promise.
    Science. 2011 Mar 25;331(6024):1553-8 PMID: 21436442
  46. Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system.
    Nature. 2005 Jul 14;436(7048):221-6 PMID: 16015321
  47. Site-specific DNA recombination in mammalian cells by the Cre recombinase of bacteriophage P1.
    Proc Natl Acad Sci U S A. 1988 Jul;85(14):5166-70 PMID: 2839833
  48. Technologically advanced cancer modeling in mice.
    Curr Opin Genet Dev. 2002 Feb;12(1):105-10 PMID: 11790563
  49. Clusterin, a haploinsufficient tumor suppressor gene in neuroblastomas.
    J Natl Cancer Inst. 2009 May 6;101(9):663-77 PMID: 19401549
  50. Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications.
    Neuropsychopharmacology. 2008 Feb;33(3):685-700 PMID: 17487225
  51. A novel basal promoter element is required for expression of the rat tyrosine hydroxylase gene.
    J Neurosci. 1997 Jun 1;17(11):4076-86 PMID: 9151724
  52. Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification.
    Br J Cancer. 2007 Jul 16;97(2):238-46 PMID: 17579628
  53. Darwinian medicine: a case for cancer.
    Nat Rev Cancer. 2007 Mar;7(3):213-21 PMID: 17301845
  54. N-myc is essential during neurogenesis for the rapid expansion of progenitor cell populations and the inhibition of neuronal differentiation.
    Genes Dev. 2002 Oct 15;16(20):2699-712 PMID: 12381668
  55. Phenotype restricted genome-wide association study using a gene-centric approach identifies three low-risk neuroblastoma susceptibility Loci.
    PLoS Genet. 2011 Mar;7(3):e1002026 PMID: 21436895
  56. Myc's broad reach.
    Genes Dev. 2008 Oct 15;22(20):2755-66 PMID: 18923074
  57. ENU-based gene-driven mutagenesis in the mouse: a next-generation gene-targeting system.
    Exp Anim. 2010;59(5):537-48 PMID: 21030782
  58. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster.
    Nat Genet. 2006 Sep;38(9):1060-5 PMID: 16878133
  59. Genome-wide screen for allelic imbalance in a mouse model for neuroblastoma.
    Cancer Res. 2000 May 1;60(9):2483-7 PMID: 10811128
  60. Global MYCN transcription factor binding analysis in neuroblastoma reveals association with distinct E-box motifs and regions of DNA hypermethylation.
    PLoS One. 2009 Dec 04;4(12):e8154 PMID: 19997598
  61. Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo.
    Neoplasia. 2009 Aug;11(8):753-62 PMID: 19649205
  62. The p53 pathway and its inactivation in neuroblastoma.
    Cancer Lett. 2003 Jul 18;197(1-2):93-8 PMID: 12880966
  63. Integrative genomics identifies LMO1 as a neuroblastoma oncogene.
    Nature. 2011 Jan 13;469(7329):216-20 PMID: 21124317
  64. Oncogene-dependent tumor suppression: using the dark side of the force for cancer therapy.
    Cold Spring Harb Symp Quant Biol. 2005;70:263-73 PMID: 16869762
  65. Therapeutic targeting of miRNAs in neuroblastoma.
    Expert Opin Ther Targets. 2010 Sep;14(9):951-62 PMID: 20658962
  66. ABCC multidrug transporters in childhood neuroblastoma: clinical and biological effects independent of cytotoxic drug efflux.
    J Natl Cancer Inst. 2011 Aug 17;103(16):1236-51 PMID: 21799180
  67. Reversible kinetic analysis of Myc targets in vivo provides novel insights into Myc-mediated tumorigenesis.
    Cancer Res. 2006 May 1;66(9):4591-601 PMID: 16651409
  68. Flp recombinase promotes site-specific DNA recombination in embryonic stem cells and transgenic mice.
    Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):6191-6 PMID: 8650242
  69. Preclinical models for neuroblastoma: establishing a baseline for treatment.
    PLoS One. 2011 Apr 29;6(4):e19133 PMID: 21559450
  70. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells.
    Oncogene. 2007 Jul 26;26(34):5017-22 PMID: 17297439
  71. Nordihydroguaiaretic acid inhibits insulin-like growth factor signaling, growth, and survival in human neuroblastoma cells.
    J Cell Biochem. 2007 Dec 15;102(6):1529-41 PMID: 17486636
  72. Small-molecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma.
    Cancer Res. 2009 Aug 15;69(16):6573-80 PMID: 19654298
  73. N-myc can functionally replace c-myc in murine development, cellular growth, and differentiation.
    Genes Dev. 2000 Jun 1;14(11):1390-9 PMID: 10837031
  74. Differential expression of myc family genes during murine development.
    Nature. 1986 Feb 27-Mar 5;319(6056):780-3 PMID: 2419762
  75. p53 mutations and loss of p53 function confer multidrug resistance in neuroblastoma.
    Med Pediatr Oncol. 2000 Dec;35(6):563-8 PMID: 11107118
  76. Targeting genes for self-excision in the germ line.
    Genes Dev. 1999 Jun 15;13(12):1524-8 PMID: 10385621
  77. Maximizing mouse cancer models.
    Nat Rev Cancer. 2007 Sep;7(9):645-58 PMID: 17687385
  78. Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma.
    Cancer Res. 2009 Jan 15;69(2):547-53 PMID: 19147568
  79. Defects in heart and lung development in compound heterozygotes for two different targeted mutations at the N-myc locus.
    Development. 1993 Oct;119(2):485-99 PMID: 8287798
  80. A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma.
    Cancer Res. 2011 Jun 1;71(11):3841-51 PMID: 21498633
  81. Embryonic lethality in mice homozygous for a targeted disruption of the N-myc gene.
    Genes Dev. 1992 Dec;6(12A):2248-57 PMID: 1459450
  82. Bmi-1 is essential for the tumorigenicity of neuroblastoma cells.
    Am J Pathol. 2007 Apr;170(4):1370-8 PMID: 17392175
  83. Myc: a weapon of mass destruction.
    Cell. 2004 Apr 16;117(2):153-6 PMID: 15084254
  84. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.
    Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5547-51 PMID: 1319065
  85. p53 is a direct transcriptional target of MYCN in neuroblastoma.
    Cancer Res. 2010 Feb 15;70(4):1377-88 PMID: 20145147
  86. Serial transcriptome analysis and cross-species integration identifies centromere-associated protein E as a novel neuroblastoma target.
    Cancer Res. 2010 Apr 1;70(7):2749-58 PMID: 20233875
  87. Slug (SNAI2) down-regulation by RNA interference facilitates apoptosis and inhibits invasive growth in neuroblastoma preclinical models.
    Clin Cancer Res. 2008 Jul 15;14(14):4622-30 PMID: 18628477
  88. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma.
    Nature. 2008 Oct 16;455(7215):967-70 PMID: 18923523
  89. c-Myc-regulated microRNAs modulate E2F1 expression.
    Nature. 2005 Jun 9;435(7043):839-43 PMID: 15944709
  90. High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma.
    Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):14094-9 PMID: 18780787
  91. Aberrant expression of BARD1 in breast and ovarian cancers with poor prognosis.
    Int J Cancer. 2006 Mar 1;118(5):1215-26 PMID: 16152612
  92. MYCN promotes the expansion of Phox2B-positive neuronal progenitors to drive neuroblastoma development.
    Am J Pathol. 2009 Aug;175(2):856-66 PMID: 19608868
  93. A highly efficient recombineering-based method for generating conditional knockout mutations.
    Genome Res. 2003 Mar;13(3):476-84 PMID: 12618378
  94. Activation of a cellular onc gene by promoter insertion in ALV-induced lymphoid leukosis.
    Nature. 1981 Apr 9;290(5806):475-80 PMID: 6261142
  95. Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma.
    Cancer Res. 2006 Aug 15;66(16):8139-46 PMID: 16912192
  96. CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas.
    J Natl Cancer Inst. 2008 Jul 2;100(13):940-9 PMID: 18577749
  97. Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis.
    Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18682-7 PMID: 18003922
  98. Direct recruitment of N-myc to target gene promoters.
    Mol Carcinog. 2000 Oct;29(2):76-86 PMID: 11074604
  99. A rapid and scalable system for studying gene function in mice using conditional RNA interference.
    Cell. 2011 Apr 1;145(1):145-58 PMID: 21458673
  100. CASZ1, a candidate tumor-suppressor gene, suppresses neuroblastoma tumor growth through reprogramming gene expression.
    Cell Death Differ. 2011 Jul;18(7):1174-83 PMID: 21252912
  101. Loss of caspase-8 expression in neuroblastoma is related to malignancy and resistance to TRAIL-induced apoptosis.
    Med Pediatr Oncol. 2000 Dec;35(6):608-11 PMID: 11107128
  102. Identification of novel gene expression targets for the Ras association domain family 1 (RASSF1A) tumor suppressor gene in non-small cell lung cancer and neuroblastoma.
    Cancer Res. 2003 Sep 1;63(17):5344-51 PMID: 14500366
  103. Common variations in BARD1 influence susceptibility to high-risk neuroblastoma.
    Nat Genet. 2009 Jun;41(6):718-23 PMID: 19412175
  104. A simple PCR method for rapid genotype analysis of the TH-MYCN transgenic mouse.
    PLoS One. 2009 Sep 04;4(9):e6902 PMID: 19730731
  105. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha.
    Science. 2010 Nov 5;330(6005):827-30 PMID: 21051638
  106. miR-19 is a key oncogenic component of mir-17-92.
    Genes Dev. 2009 Dec 15;23(24):2839-49 PMID: 20008935
  107. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins.
    Nucleic Acids Res. 1995 May 25;23(10):1686-90 PMID: 7784172
  108. A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene.
    Mol Cancer Res. 2008 May;6(5):735-42 PMID: 18505919
  109. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants.
    Nature. 2005 Aug 11;436(7052):807-11 PMID: 16094360
  110. Genome-wide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in human tumors.
    Cancer Res. 2003 Sep 1;63(17):5266-73 PMID: 14500357
  111. c- and N-myc regulate neural precursor cell fate, cell cycle, and metabolism to direct cerebellar development.
    Cerebellum. 2010 Dec;9(4):537-47 PMID: 20658325
  112. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour.
    Nature. 1983 Sep 15-21;305(5931):245-8 PMID: 6888561
  113. Targeted expression of MYCN causes neuroblastoma in transgenic mice.
    EMBO J. 1997 Jun 2;16(11):2985-95 PMID: 9214616
  114. Expression and sequence analysis of candidates for the 1p36.31 tumor suppressor gene deleted in neuroblastomas.
    Oncogene. 2008 Jan 31;27(6):803-10 PMID: 17667943
  115. Proteins of the Myc network: essential regulators of cell growth and differentiation.
    Adv Cancer Res. 1996;68:109-82 PMID: 8712067
  116. The ups and downs of Myc biology.
    Curr Opin Genet Dev. 2010 Feb;20(1):91-5 PMID: 19962879
  117. Histological profile of tumours from MYCN transgenic mice.
    J Clin Pathol. 2008 Oct;61(10):1098-103 PMID: 18682419
  118. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.
    Cancer Res. 2004 Dec 15;64(24):8816-20 PMID: 15604238
  119. Germline PHOX2B mutation in hereditary neuroblastoma.
    Am J Hum Genet. 2004 Oct;75(4):727-30 PMID: 15338462
  120. Minimal residual disease at the time of peripheral blood stem cell harvest in patients with advanced neuroblastoma.
    Med Pediatr Oncol. 2001 Jan;36(1):213-9 PMID: 11464888
  121. NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome.
    Cell. 2010 Jul 23;142(2):218-29 PMID: 20655465
  122. Chronic inflammation and cancer: the role of the mitochondria.
    Oncology (Williston Park). 2011 Apr 30;25(5):400-10, 413 PMID: 21710835
  123. Sleep-disordered breathing in newborn mice heterozygous for the transcription factor Phox2b.
    Am J Respir Crit Care Med. 2005 Jul 15;172(2):238-43 PMID: 15860752
  124. Modeling chromosomes in mouse to explore the function of genes, genomic disorders, and chromosomal organization.
    PLoS Genet. 2006 Jul;2(7):e86 PMID: 16839184
  125. Establishment of a novel neuroblastoma mouse model.
    Int J Oncol. 2008 Dec;33(6):1195-9 PMID: 19020752
  126. MicroRNA-34a is a potent tumor suppressor molecule in vivo in neuroblastoma.
    BMC Cancer. 2011 Jan 25;11:33 PMID: 21266077
  127. Loss of N-myc function results in embryonic lethality and failure of the epithelial component of the embryo to develop.
    Genes Dev. 1992 Dec;6(12A):2235-47 PMID: 1459449
  128. Temporal dissection of p53 function in vitro and in vivo.
    Nat Genet. 2005 Jul;37(7):718-26 PMID: 15924142
  129. N-myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis.
    EMBO J. 2001 Mar 15;20(6):1383-93 PMID: 11250904
  130. Exploring the sequence space for tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity.
    Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):7963-8 PMID: 10859354
  131. Molecular characterization of tumors from a transgenic mouse adrenal tumor model: comparison with human pheochromocytoma.
    Int J Oncol. 2010 Sep;37(3):695-705 PMID: 20664939
  132. N-myc and c-src genes are differentially regulated in PCC7 embryonal carcinoma cells undergoing neuronal differentiation.
    J Cell Physiol. 1986 May;127(2):274-80 PMID: 3700483
  133. Prevalence and functional consequence of PHOX2B mutations in neuroblastoma.
    Oncogene. 2008 Jan 17;27(4):469-76 PMID: 17637745
  134. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF.
    Genes Dev. 1999 Oct 15;13(20):2678-90 PMID: 10541554
  135. Flp-mediated tissue-specific inactivation of the retinoblastoma tumor suppressor gene in the mouse.
    Oncogene. 1998 Jul 9;17(1):1-12 PMID: 9671308
  136. Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma.
    Oncogene. 2005 Apr 14;24(16):2684-94 PMID: 15829979
  137. Modeling the therapeutic efficacy of p53 restoration in tumors.
    Cell. 2006 Dec 29;127(7):1323-34 PMID: 17182091
  138. ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma.
    Cancer Res. 2008 Dec 1;68(23):9735-45 PMID: 19047152
  139. High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma.
    Clin Cancer Res. 2010 Feb 15;16(4):1108-18 PMID: 20145180
  140. The homeobox gene Phox2b is essential for the development of autonomic neural crest derivatives.
    Nature. 1999 May 27;399(6734):366-70 PMID: 10360575
  141. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma.
    J Clin Invest. 2007 Feb;117(2):326-36 PMID: 17235397
  142. PHOX2B-mediated regulation of ALK expression: in vitro identification of a functional relationship between two genes involved in neuroblastoma.
    PLoS One. 2010 Oct 01;5(10): PMID: 20957039
  143. Isolation and propagation of enteric neural crest progenitor cells from mouse embryonic stem cells and embryos.
    Development. 2010 Mar;137(5):693-704 PMID: 20147374
  144. Childhood tumors of the nervous system as disorders of normal development.
    Curr Opin Pediatr. 2006 Dec;18(6):634-8 PMID: 17099362
  145. The MYCN oncogene is a direct target of miR-34a.
    Oncogene. 2008 Sep 4;27(39):5204-13 PMID: 18504438
  146. Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival.
    PLoS One. 2009 Nov 16;4(11):e7850 PMID: 19924232
  147. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification.
    Clin Cancer Res. 2010 Sep 1;16(17):4353-62 PMID: 20719933
  148. High mobility group A1 is a molecular target for MYCN in human neuroblastoma.
    Cancer Res. 2005 Sep 15;65(18):8308-16 PMID: 16166307
  149. Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma.
    Cancer Res. 2007 Oct 1;67(19):9435-42 PMID: 17909053
  150. Genetics and genomics of neuroblastoma.
    Cancer Treat Res. 2010;155:65-84 PMID: 20517688
  151. Expression of N-myc and MRP genes and their relationship to N-myc gene dosage and tumor formation in a murine neuroblastoma model.
    Med Pediatr Oncol. 2000 Dec;35(6):585-9 PMID: 11107123
  152. Evidence for nm23 RNA overexpression, DNA amplification and mutation in aggressive childhood neuroblastomas.
    Oncogene. 1993 Apr;8(4):855-65 PMID: 8384356
  153. Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays.
    PLoS One. 2007 Feb 28;2(2):e255 PMID: 17327916
  154. The Phox2 homeodomain proteins are sufficient to promote the development of sympathetic neurons.
    Development. 1999 Sep;126(18):4087-94 PMID: 10457017
  155. Activating PTPN11 mutations play a minor role in pediatric and adult solid tumors.
    Cancer Genet Cytogenet. 2006 Apr 15;166(2):124-9 PMID: 16631468
Article Info
Journal
Seminars in cancer biology
Abbr.
Semin Cancer Biol
ISSN
1096-3650
DOI
10.1016/j.semcancer.2011.09.011
Email
louis.chesler@icr.ac.uk
Published
2011-10-00
Epub
2011-00-21
Pages
245-55
Language
English
Region
England
NLM ID
9010218
PMCID
PMC3504935
Subset
IM
Grants
NCI NIH HHS · U54 CA163155 · United States
NCI NIH HHS · R01 CA102321 · United States
NCI NIH HHS · R01 CA133091 · United States
NCI NIH HHS · P01 CA081403 · United States
NCI NIH HHS · R01 CA159859 · United States
NINDS NIH HHS · R01 NS055750 · United States
NCI NIH HHS · R01 CA148699 · United States
External Links
PubMed source DOI: 10.1016/j.semcancer.2011.09.011 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2